Hindawi Publishing CorporationEvidence-Based Complementary and Alternative MedicineVolume 2013, Article ID 942541, 9 pageshttp://dx.doi.org/10.1155/2013/942541Research ArticleTwo New 3,4;9,10-seco-Cycloartane Type Triterpenoids fromIllicium difengpi and Their Anti-Inflammatory ActivitiesChuntong Li,1 Fengmin Xi,1 Junling Mi,2 Zhijun Wu,1 and Wansheng Chen11 Department of Pharmacy, Shanghai Changzheng Hospital, Second Military Medical University, Fengyang Road 415,Shanghai 200003, China2 School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Liutai Road 1166, Chengdu, Sichuan 611137, ChinaCorrespondence should be addressed to Zhijun Wu; wuzhijun999@sina.comand Wansheng Chen; chenwanshengsmmu@yahoo.com.cnReceived 31 January 2013; Revised 17 April 2013; Accepted 18 April 2013Academic Editor: Molvibha VongsakulCopyright Â© 2013 Chuntong Li et al. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.A pair of new 3,4;9,10-seco-cycloartane type triterpenoid stereoisomerides: 24R,25-dihydroxy-3,4;9,10-seco-4(28)-cycloarten-10,3-olide (1) named Illiciumolide A and 24S,25-dihydroxy-3,4;9,10-seco-4(28)-cycloarten-10,3-olide (2) named Illiciumolide Bwere isolated from the stem bark of Illicium difengpi, as well as five known biogenetically related triterpenoids, includingsootepin E (3), betulinic acid (4), lupeol (5), (all-Z)-1,5,9,13,17,21-hexamethyl-1,5,9,13,17,21-cyclotertracosahexaene (6), and (all-E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene (7). The structures of two new compounds were determined on thebasis of spectroscopic analysis including 1D-, 2D-NMR, and MS techniques. Two assays were conducted: inhibition of tumornecrosis factor-alpha (TNF-ğ›¼) and inhibition of nuclear factor kappa B (NF-ğœ…B) in RAW264. 7 cells induced by lipopolysaccharide(LPS). It was observed that compounds 1, 2 and 7 showed significant inhibition of TNF-ğ›¼ production and NF-ğœ…B release. Themolecule docking results showed that compounds 1 and 2 got high fitness scores with dual specificity mitogen-activated proteinkinase kinase 1 (MPKK1), whose activation plays a pivotal role between TNF-ğ›¼ and activation of NF-ğœ…B. The anti-HIV-1 potencyof compounds 1â€“5 was also discussed, in addition to the results of computer-aided screening for targets.1. IntroductionNatural products have been, and continue to be, a majorsource of pharmacologically active substances from whichdrugs can be developed [1]. Medicinal plants that can relieverheumatism, chills, and pains according to traditional Chi-nese medicine theory are fit for use by rheumatism sufferers.From these plants, many constituents with proved anti-inflammatory activity have been isolated and their structureswere determined by spectroscopic methods.I. difengpi (Illiciaceae), the stem bark of which has beenapplied for treatment of rheumatoid arthritis as a traditionalChinese medicine, is a small shrub growing in mountainareas of Guangxi province in China. I. difengpi is listed inChinese Pharmacopoeia. In previous phytochemical investi-gation of barks of I. difengpi thirty compounds were isolatedincluding dominant phenylpropanoids and neolignans [2â€“4] together with four sesquiterpene lactones [5] and threetriterpenoids [6]. The anti-inflammatory activities of severalneolignans were assayed by measuring the inhibitory ratioof ğ›½-glucuronidase release in rat PMNs induced by PAF invitro [2, 5]. The sesquiterpene lactones were predicted toexhibit neurotrophic activity [7â€“9]. However, there have beenlimited studies that focus on the triterpenoids from I. difengpiand of the family Illiciaceae. Until now, only six cycloartanes[6, 10, 11] were reported to be isolated from family Illiciaceae,while from family Schisandraceae (Schisandra and Kadsura,order Illiciales) more than 150 triterpenoids [12] have beenisolated. In particular, they both contain seco-cycloartanetriterpenoids. These characteristic chemical structures fromthe Schisandraceae and their activities were widely studied.Most of the seco-cycloartanes from the family Schisandraceaewere demonstrated to possess anti-HIV-1 activity.As a part of our study to find the active constituents,an investigation of I. difengpi was undertaken, leading toisolation and structural elucidation of two new 3,4;9,10-seco-cycloartane triterpenoids and three known triterpenoidstogether with two squalenes. In order to shed some light on2 Evidence-Based Complementary and Alternative Medicinebiological activities, the anti-inflammatory and anti-HIV-1properties of the isolates were evaluated and discussed.2. Materials and Methods2.1. General Experimental Procedures. Optical rotations weremeasured using a Perkin-Elmer 341 polarimeter. IR spectrawere recorded on aNEXUS 470 FT-IR spectrometer (ThermoNicolet, USA). 1D (1H, 13C, DEPT) and 2D (COSY, NOESY,HSQC, HMBC) NMR spectra were acquired on a BrukerAvance 600 NMR spectrometer operating at 600 (1H) or 150(13C) MHz using the residual solvent signals as an internalreference (CDCl3ğ›¿H 7.26 ppm, ğ›¿C 77.0 ppm). NMR sampleswere in 3mm Shigemi tubes during NMR analyses. High-resolution mass spectrometric data were obtained on anAgilent 6220 TOF LC/MS instrument (Agilent Technolo-gies, MA, USA) with ESI ionization in the positive mode.Column chromatography (CC) was performed on SephadexLH-20 gel (40â€“70 ğœ‡m, Amersham Pharmacia Biotech AB,Uppsala, Sweden), YMC-GRL ODS-A (50 ğœ‡m; YMC, MA,USA), and silica gel H (100â€“200 and 200â€“300mesh, QingdaoHaiyang Chemical Co. Ltd., Qingdao, China). TLC analyseswere performed on Si60F254plates and visualized under UVlight or by heating after spraying with 10% H2SO4/EtOHsolution. Semipreparative RP-HPLC isolation was achievedwith an Agilent 1200 instrument using a YMC 5 ğœ‡m C18column (250mm Ã— 10 nm) eluted with 80% MeCN/H2Oat 1-2mL/min. Peak detection was made with a refractiveindex detector (RID). The positive controls in the anti-inflammatory assaywere tripterygium tablets (TRT) and totalglucosides of paeony (TGP). Purity was assessed by HPLCand determined to be 95% or greater for compounds 1â€“7 atthe time of testing.2.2. Plant Material. The stem barks of Illicium difengpi werepurchased from Caitongde Pharmacy, Shanghai, China, inJanuary 2010. Plant material was authenticated by Profes-sor Lianna Sun (Department of Pharmacognosy, School ofPharmacy, Second Military Medical University) based onmorphological characters. Voucher specimen (No. 20100110)has been deposited at the Herbarium of Department of Phar-macognosy, School of Pharmacy, Second Military MedicalUniversity, Shanghai, China.2.3. Extraction and Isolation. The air-dried stem bark of I.difengpi (40 kg) was powdered and extracted three times with80% ethanol under reflux. The solvent was concentrated toobtain a crude extract (1200 g) which was suspended in water(10 L) and extracted with petroleum ether (10 L Ã— 3), EtOAc(10 L Ã— 3), and BuOH (10 L Ã— 3), affording 40, 560, and 300 gof each dried fraction, respectively.The dried petroleum ether fraction (Fr.1) (40 g) was chro-matographed on silica gel column (CC) (80 Ã— 5 cm, gradientwith petroleum ether: EtOAc = 100 : 0â†’ 0 : 100) to give eightmain fractions (Fr.1-1â€“Fr.1âˆ’8), among which Fr.1-2 gave com-pound 7 (27mg), Fr.1âˆ’7provided compound 6 (85mg), andFr.1âˆ’8afforded compound 3 (34mg) through Sephadex LH-20 CC (150 Ã— 2 cm, CH2Cl2: MeOH= 1 : 1).The EtOAc extract(Fr.2) (560 g) was chromatographed on silica gel CC (150 Ã—10 cm, gradient with CH2Cl2: MeOH = 300 : 1â†’ 0 : 100) togive four main fractions (Fr.2-1â€“Fr.2âˆ’4). Fr.2-2 was subjectedto silica gel CC (20 Ã— 2 cm, gradient with petroleum ether:EtOAc = 100 : 1â†’ 1 : 1) affording a mixture of compounds 4and 5.Themixture was rechromatographed using silicaODS-A gel CC (20 Ã— 2 cm, gradient with MeOH: H2O = 1 : 1â†’1 : 0) to give pure compounds 4 (45mg) and 5 (21mg). Fr.2-3was fractionated by silica gel CC (35 Ã— 3 cm, gradient withpetroleum ether: EtOAc = 100 : 1â†’ 5 : 1) to yield three sub-fractions (Fr.2-3-1â€“Fr.2-3-3). Fr.2-3-3 was rechromatographedusing semipreparative HPLC system (Agilent 1200 series;YMCHPLCC18 column-5ğœ‡m, 250 Ã— 10mm, refractive indexdetector; flow 2mL/min; mobile phaseMeCN: H2O= 80 : 20)to give pure compounds 1 (8mg) and 2 (2.5mg).2.4. Characterization of Compounds. Compound 1: yellowishsolid; [ğ›¼]25ğ·+ 41.2 (c 0.5, MeOH); IR (KBr) ]max 3402, 2929,2872, 1763, 1458, 1377, 1273, 1238, 1194, 1172, 1074, 1041, 1007,899 cmâˆ’1; 1HNMR and 13CNMRdata see Table 1; HRESIMSm/z 475.3774 [M+H]+ (calcd. for C30H51O4, 475.3784).Compound 2: yellowish solid; [ğ›¼]25ğ·+ 94.0 (c 0.5,MeOH);IR (KBr) ]max 3454, 2931, 2873, 1764, 1461, 1452, 1379, 1259,1195, 1171, 1080, 1039, 1009, 920, 870 cmâˆ’1; 1H NMR and13C NMR data see Table 1; HRESIMS ğ‘š/ğ‘§ 475.3765 [M+H]+(calcd. for C30H51O4, 475.3784).2.5. Inhibition of TNF-ğ›¼ Release Assay. Isolated compoundswere tested for their ability to inhibit TNF-ğ›¼ release fromLPS-stimulated RAW 264.7 macrophages using enzyme-linked immunosorbent assay (ELISA) as a quantitative assay.Tripterygium tablets (TRT) and total glucosides of paenia(TGP) were used as positive controls. The ELISA Max setstandard (BioLegend, San Diego, CA, USA) was performedaccording to the manufacturerâ€™s instruction strictly. Theinhibition ratio (IR) was calculated as IR (%) = (ğ´LPS âˆ’ğ´S)/ğ´LPS Ã— 100%, whereğ´LPS andğ´S refer to the amount ofTNF-ğ›¼ in cells pretreated with LPS and samples, respectively.2.6. Inhibition of NF-ğœ…B Release Assay. The effect ofcompounds 1â€“7 on NF-ğœ…B production from LPS-treatedRAW264.7 cells was monitored. Tripterygium tablets (TRT)and total glucosides of paeony (TGP) were used as positivecontrols. Cells were placed on 96-well plates (Costar) ata density of 1.0 Ã— 105 cells mLâˆ’1, maintained in DMEMcontaining 10% FBS for 24 h. After changing the medium,the samples were incubated at 37âˆ˜C with 5% CO2for 4 h,and 1 ğœ‡g/mL LPS was then added and incubated for another48 h. After 48 h, cells were collected and completely crackedusing 1Ã— lysis buffer. After centrifugation at 1500 rpm for5min, the supernatant was obtained. 100ğœ‡L luciferase assayreagent and 20ğœ‡L cell lysate were added to it in orderrapidly. The detection results were read in 10 s. The IRwas calculated in a similar way to the above formula,IR (%) = (ğ¼LPS âˆ’ ğ¼S)/ğ¼LPS Ã— 100%, where ğ¼LPS and ğ¼S refer tothe fluorescence intensity of cells pretreated with LPS andsamples, respectively.Evidence-Based Complementary and Alternative Medicine 3Table 1: 1H-NMR (600MHz) and 13C-NMR (150MHz) data for compounds 1 and 2 (CDCl3, ğ›¿H in ppm, ğ½ in Hz).Position 1 2ğ›¿C, mult. ğ›¿H ğ›¿C, mult. ğ›¿H1 31.5, CH22.33 (m, Hb-1)1.77â€“1.84 (m, Ha-1)31.5, CH22.30â€“2.36 (m, Hb-1)1.70â€“1.76 (m, Ha-1)2 29.6, CH22.41â€“2.48 (m, Ha-2)2.41â€“2.48 (m, Hb-2)29.6, CH22.42â€“2.48 (m, Ha-2)2.42â€“2.48 (m, Hb-2)3 177.3, qC â€” 177.3, qC â€”4 146.6, qC â€” 146.6, qC â€”5 54.8, CH 2.54 (d, 9.6, H-5) 54.8, CH 2.56 (d, 9.8, H-5)6 31.4, CH21.65â€“1.70 (m, Ha-6)1.82â€“1.89 (m, Hb-6)31.4, CH21.61â€“1.67 (m, Ha-6)1.82â€“1.89 (m, Hb-6)7 30.5, CH21.46â€“1.51 (m, Ha-7)1.79â€“1.83 (m, Hb-7)30.5, CH21.41â€“1.46 (m, Ha-7)1.72â€“1.77 (m, Hb-7)8 48.4, CH 1.43 (dd, 3.2, 7.0, H-8) 48.4, CH 1.42â€“1.47 (m, H-8)9 31.7, CH 1.90 (td, 7.4, 14.0, H-9) 31.7, CH 1.85â€“1.92 (m, H-9)10 91.7, qC â€” 91.7, qC â€”11 29.6, CH21.23 (m, Ha-11)1.73 (m, Hb-11)29.6, CH21.46 (m, Ha-11)1.73 (m, Hb-11)12 32.7, CH21.61â€“1.64 (m, Ha-12)1.75â€“1.80 (m, Hb-12)32.7, CH21.61â€“1.64 (m, Ha-12)1.75â€“1.80 (m, Hb-12)13 45.5, qC â€” 45.5, qC â€”14 49.2, qC â€” 49.2, qC â€”15 33.3, CH21.06â€“1.14 (m, Ha-15)1.23â€“1.28 (m, Hb-15)34.0, CH20.97â€“1.02 (m, Ha-15)1.23â€“1.25 (m, Hb-15)16 27.9, CH21.37â€“1.42 (m, Ha-16)1.92â€“1.98 (m, Hb-16)27.8, CH21.47 (m, Ha-16)1.92â€“1.98 (m, Hb-16)17 51.0, CH 1.49â€“1.53 (m, H-17) 50.9, CH 1.49â€“1.55 (m, H-17)18 14.7, CH3 0.80 (s, H3-18) 14.7, CH3 0.80 (s, H3-18)19 49.2, CH21.64â€“1.70 (m, Ha-19)1.77â€“1.83 (m, Hb-19)49.2, CH21.64â€“1.70 (m, Ha-19)1.78â€“1.83 (m, Hb-19)20 35.9, CH 1.37â€“1.47 (m, H-20) 36.4, CH 1.51â€“1.55 (m, H-20)21 18.3, CH3 0.86 (d, 7.22, H3-21) 18.6, CH3 0.88 (d, 6.5, H3-21)22 33.1, CH21.13â€“1.20 (m, Ha-22)1.35â€“1.40 (m, Hb-22)33.3, CH21.13â€“1.20 (m, Ha-22)1.35â€“1.40 (m, Hb-22)23 28.3, CH21.36 (m, Ha-23)1.14â€“1.22 (m, Hb-23)28.6, CH21.36 (m, Ha-23)1.09â€“1.14 (m, Hb-23)24 78.7, CH 3.31 (t, 6.2, H-24) 79.6, CH 3.27 (dd, 9.5, 1.6, H-24)25 73.2, qC â€” 73.2, qC â€”26 23.2, CH3 1.14 (s, H3-26) 23.2, CH3 1.15 (s, H3-26)27 26.6, CH3 1.19 (s, H3-27) 26.5, CH3 1.21 (s, H3-27)28 16.6, CH3 0.83 (s, H3-28) 16.7, CH3 0.84 (s, H3-28)29 22.6, CH3 1.76 (s, H3-29) 22.6, CH3 1.77 (s, H3-29)30 115.0, CH24.80 (s, Ha-30)4.91 (s, Hb-30)115.0, CH24.81 (s, Ha-30)4.92 (s, Hb-30)2.7. Statistical Analysis. The statistical significance of dif-ferences was determined by two-tailed Studentâ€™s ğ‘¡-test forunpaired data.3. Results and Discussion3.1. Structure Analysis. Illiciumolide A (1) was isolated asa yellowish solid. The positive HRESI-MS analysis showeda pseudo-molecular ion at ğ‘š/ğ‘§ 475.3774 [M+H]+, consis-tent with the formula C30H50O4(calcd. 474.3709), whichaccounted for six degrees of unsaturation. IR (KBr) absorp-tion bands were observed as 3402 cmâˆ’1 (OH), 2929 cmâˆ’1(CH3), 1763 cmâˆ’1 (C=O), 1377 cmâˆ’1 (CH2), and 899 cmâˆ’1(C=CH2). The 13C NMR and DEPT spectra exhibited thirtyresonances, including six quaternary carbons, six methines,twelve methylenes, and six methyls. Among these, five4 Evidence-Based Complementary and Alternative MedicineHOOHHOOHOOHHHHH367R1234 56 7891011 1213141516171819 20212223 24 252627292830R11R = (24R)-OH2 R = (24S)-OH4 R1 = COOH5 R1 = CH3Figure 1: Structures of compounds 1â€“7.primary methyls (ğ›¿C 14.7, H3-18; ğ›¿C 16.6, H3-28; ğ›¿C 22.6,H3-29; ğ›¿C 23.2, H3-26; ğ›¿C 26.5, H3-27) and a secondarymethyl (ğ›¿C 18.3,H3-21)were determined as evident from theirmultiplicities in the 1H NMR spectrum (Table 1). The 13CNMR spectrum of 1 revealed the presence of one lactonecarbonyl carbon (ğ›¿C 177.3) and a pair of olefinic carbons(ğ›¿C 146.6, ğ›¿C 115.0). Taking into consideration the presenceof a pair of methylene protons (ğ›¿H 4.80 and 4.91) in the1H NMR spectrum of 1 (Table 1), these features indicatedthe existence of a terminal methylene group in accordancewith the IR spectrum absorption.The oxygenated quaternarycarbon appeared at the low field ğ›¿C 91.7, together with thelactone carbonyl carbon (ğ›¿C 177.3), suggesting that the C-3 (ğ›¿C 177.3) may lactonize to C-10 (ğ›¿C 91.7) forming afive-membered lactone ring, which required future analysisof HMBC and 1H-1H COSY. Apart from two degrees ofunsaturation occupied by one double bond and one carbonyl,the remaining four degrees of unsaturation indicated that 1should possess a tetracyclic system. Detailed comparison ofthe 1Hand 13CNMRspectra of 1with those of schisanterpeneA [13] suggested a similar structure for rings Aâ€“D in bothcompounds and might be derived from cycloartane typetriterpenoids, but a pair of double bonds between C-24 andC-25 and the carboxyl group at C-26 in schisanterpene Awas absent in 1, which instead exhibited vicinal diol (C-24, ğ›¿C 78.7; C-25, ğ›¿C 73.2) and two methyls (C-26, ğ›¿C 23.2;C-27, ğ›¿C 26.5). As a result, 1 was tetracyclic and belongedto 3,4;9,10-seco-type triterpenoids [13, 14]. Subsequently, thestructure was fully elucidated by 2D NMR spectroscopy. TheH2-1, H2-2, and H-5 showed distant correlations with C-3, C-10, and C-19, coupled with 1H-1H COSY correlationof H-1/H-2 (Figure 2), consistent with the lactone ring (A)substructure. A detailed analysis of its HSQC, HMBC and1H-1H COSY spectra confirmed that 1 contained a seven-membered ring (B) evident as the HMBC correlations fromH-5 to C-10, from H-6 to C-8, from H-7 to C-5, and C-9and from H-19 to C-9 and C-10, as well as 1H-1H COSYcorrelations of H-5/H-6/H-7 and H8/H-9 (Figure 2). Thestructure of rings C and D was deduced from the 1H-1HCOSY correlations of H-9/H-11/H-12 and H-15/H-16/H-17and HMBC correlations from H3-13 to C-8 and C-15, H3-14 to C-12 and C-17, and H-11 to C-19 and C-14. From theabove deduction, compound 1 and schisanterpene A wereconfirmed to have the similar structure in rings Aâ€“D, whilethe chain fromC-17 was verifiably different. Further evidencesupporting chain structure was provided by the presence ofthe correlations of H-15/H-16, H-21/H-20, H-22/H-23, andH-23/H-24 as deduced from the COSY spectrum andHMBCEvidence-Based Complementary and Alternative Medicine 51H-1H COSYOHOHOOHMBC (Hâ†’C)Figure 2: Key 1H-1H COSY (bold lines) and HMBC (Hâ†’C)correlations of compound 1.correlation from H-23 to C-20. Furthermore, the vicinal diolwith two methyls termination was proved from the HMBCevident correlations from H3-26 (H3-27) to C-24 and C-25(Figure 2). The relative stereochemistry of compound 1 wasdeduced from NOESY correlations (Figure 3). The oxygenatom of the spiroring on C-10 was in the ğ›¼-orientation, as theNOESY correlations between H-2ğ›½ and H2-19 and H-1ğ›½ andH3-29 are the same as those of schinalactone B. Correlationsbetween H-5ğ›¼ with H-7ğ›¼ and H-9 clearly showed that theseprotons were on the same face. Other important NOESYcorrelations were observed between H-9 and H-11ğ›¼ and H3-28, andH-7ğ›¼/H-16ğ›¼, indicating that H3-28 was ğ›¼-orientationwhile H3-18 was on the other side. Finally about the C-17side chain, the intense cross-peaks between H-16ğ›¼, H-17, andH3-21 suggested that both H-17 and C-21 have ğ›¼ orientationin 1. Except for 24-OH, the relative configurations of 1 werethe same as schinalactone B. The 24-OH configuration wasdeduced by the resonances of protons and carbons at C-23,C-24, and C-25 and by the ğ½ values between H-23 and H-24(ğ½ = 6.2Hz). In the previous literature, ğ½ value between H-23 and H-24 in 24R-configuration was reported to be around6.5 and 1.0Hz, while that in 24S-configuration was around10.5 and 1.9Hz [15, 16]. Comparison with the literature dataand significant NOE correlations between H-24 and H-23ğ›¼, alone with modeling in Chem3D 11.0 (Cambridge Soft,Inc.) as shown in Figure 3, both suggested 24-OH was R-configuration. Based on these evidences, the structure of 1was determined to be 24R,25-dihydroxy-3,4;9,10-seco-4(28)-cycloarten-10,3-olide (Figure 1).Illiciumolide B (2) was obtained as a yellowish solidwith molecular formula C30H50O4established by positiveHRESI-MS (ğ‘š/ğ‘§ 475.3765 [M+H]+, calcd. for 475.3784).Both compounds 1 and 2 have the same molecular formula,suggesting that they are isomer. The 1H and 13C NMRspectra of 1 were quite similar to those of 2. In comparisonwith their 1H and 13C NMR data (Table 1), it was foundthat the chemical shifts of C-20, C-21, C-22, C-23, and C-24 were slightly different, while the other chemical shiftsremained unchanged. These suggested that compound 2was a stereoisomer of 1, which was confirmed by the NOEspectrum. In the NOE experiments, correlation signal from125199281720212324262522291H-1H NOEFigure 3: Key NOE correlations of compound 1.H-24 to H-23ğ›½ (ğ›¿H 1.09â€“1.14) in 2 was observed, while H-24 to H-23ğ›¼ (ğ›¿H 1.36) in compound 1 was observed. Besides,the ğ½ value between H-23 and H-24 (ğ½ = 9.5, 1.6Hz) wasdifferent with that (ğ½ = 6.2Hz) of compound 1. By compar-ison with the literature [15, 16], compound 2 was deducedto be 24S-configuration. Therefore, compound 2 was elu-cidated as 24S,25-dihydroxy-3,4;9,10-seco-4(28)-cycloarten-10,3-olide (Figure 1). The spectra of Illiciumolide A and Bare presented in Supplementary Materials available online athttp://dx.doi.org/10.1155/2013/942541, including MS, IR, andNMR spectra.In addition to the two new compounds, the knowntriterpenoids 3 [15, 17, 18], 4 [19, 20], and 5 [21, 22], andsqualenes 6 [23] and 7 [24] were also isolated from the I.difengpi. This is the first report on isolation of compounds3, 6, and 7 and 3,4-seco- and 3,4;9,10-seco-type triterpenoidsfrom I. difengpi.3.2. Bioactivities Analysis3.2.1. Inhibition of TNF-ğ›¼ Release Assay. The antiinflamma-tory activities of compounds 1â€“7 at 25 ğœ‡g/mL were assessedby determining the inhibitory ratio of TNF-ğ›¼ release in LPS-stimulated RAW 264.7 macrophages in vitro. Tripterygiumtablets (TRT) and total glucosides of paenia (TGP) were usedas positive controls. As shown in Figure 4, the concentrationsof TNF-ğ›¼ in the RAW 264.7 cells pretreated with compounds1, 2, and 7 were reduced by 90%, 85%, and 91%, respectively,compared to LPS-stimulated RAW 264.7 cells, while theinhibitory rates of two positive controls TRT and TGP were59% and 49%, respectively. These results demonstrated thatcompounds 1, 2, and 7 had a significant inhibitory effect onTNF-ğ›¼ release from macrophages.3.2.2. Inhibition of NF-ğœ…B Release Assay. Based on the resultsobtained from TNF-ğ›¼ release experiments, compounds 1â€“7 were further assessed for their possible effect on NF-ğœ…Bproduction from RAW 264.7 cells stimulated with LPS. Thecytotoxic effects of tested compounds on LPS-stimulatedRAW 264.7 cells were determined initially. The resultsshowed that compounds 1â€“5 did not affect cell viabilityat concentrations up to 25ğœ‡g/mL and 6 and 7 did up to100 ğœ‡g/mL. Compound 1 at concentration 10 ğœ‡g/mL and6 Evidence-Based Complementary and Alternative Medicine1009080706050402030100âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—Inhibition of TNF-ğ›¼production (%)NormalLPSTRTTGP 1 2 3 4 5 6 7Test compound numberFigure 4: Inhibitory rate of TNF-ğ›¼ production fromLPS-stimulatedRAW264.7 cells by compounds 1â€“7 at a concentration of 25mg/mL.âˆ—âˆ—ğ‘ƒ < 0.01 for TNF-ğ›¼ levels in RAW 264.7 cells treated with LPS inthe presence of the test compounds versus that in the absence of thetest compounds.20ğœ‡g/mL, 2 at 20ğœ‡g/mL, and 7 at 90ğœ‡g/mL greatly reducedthe NF-ğœ…B production stimulated by LPS (ğ‘ƒ < 0.01). It wasobserved that these compounds showed a dose-dependentinhibition of NF-ğœ…B release in LPS-stimulated RAW264.7cells. The remaining compounds showed slight activitiesagainst NF-ğœ…B release (Figure 5).3.2.3. Molecule Docking Screening for Targets. Binding prop-erties for compounds 1, 3, 4, and 5 on various inflammationrelated ligands were estimated by computer-aided moleculardocking. The results showed that all these compounds hadgood binding with dual specificity mitogen-activated proteinkinase kinase 1 (MPKK1), whose activation is involved inthe upstream of NF-ğœ…B signal pathway [1], followed by pro-duction of many proinflammatory cytokines as well as otherimportant inflammation-released proteins (see Table 2).Similar computer-aided molecule docking to screen tar-gets had been calculated and several ligands, including gag-pol polyprotein, protease, androgen receptor, and renin,exhibited high fit score and norm fit score (Table 3).3.3. Discussion. This is the first time that 3,4;9,10-seco-typecycloartane triterpenoids were isolated from I. difengpi andfrom genus Illicium. There has been only five cycloartanetriterpenoids [10], two of which were 3,4-seco-cycloartanetype triterpenoids [11], isolated from family Illiciaceae. Theseseco-cycloartane types of triterpenoids have been extensivelyisolated from family Schisandraceae, especially 46 com-pounds of 3,4-seco-cycloartane type out of 166 triterpenoidstotally [22]. It was widely accepted that family Illiciaceaehas close relationship with theSchisandraceae (Schisandraand Kadsura) and both of them were under the Illiciales.The common possession of the seco-cycloartanes in both I.difengpi and the Schisandraceae is of great significance.I. difengpi is included in Chinese Pharmacopoeia forits traditional treatment of rheumatoid arthritis (RA). InRA patients, TNF-ğ›¼ levels are elevated in RA synovial1009080706050402030100âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—Inhibition of NF-ğœ…Bproduction (%)NormalLPSTRTTGP6 7Tested compound number90ğœ‡g/mL30ğœ‡g/mL10ğœ‡g/mL(a)100806040200âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—âˆ—Inhibition of NF-ğœ…Bproduction (%)NormalLPSTRTTGP1 2 3 4 5Tested compound number20ğœ‡g/mL10ğœ‡g/mL5ğœ‡g/mL(b)Figure 5: Inhibitory rate of NF-ğœ…B production from LPS-stimulatedRAW 264.7 cells by (a) Compounds 6-7 at three concentrations90 ğœ‡g/mL, 30 ğœ‡g/mL, and 10ğœ‡g/mL. (b) Compounds 1â€“5 at threeconcentrations 20ğœ‡g/mL, 10 ğœ‡g/mL, and 5 ğœ‡g/mL. âˆ—ğ‘ƒ < 0.05 andâˆ—âˆ—ğ‘ƒ < 0.01 for TNF-ğ›¼ levels in RAW 264.7 cells treated with LPS inthe presence of the test compounds versus that in the absence of thetest compounds.fluid, serum, and synovial fibroblasts [25]. Macrophages areimportant cells implicated in the initiation of inflammatoryresponses, so the agents that inhibit TNF-ğ›¼ production havebeen studied almost exclusively in these cells. The objectiveof this present study was to investigate the potential activitiesagainst RA of triterpenoids isolated from the I. difengpiagainst RA. The main focus was to explore the attenuationof LPS-induced acute inflammatory response under in vitroconditions. Our research results suggested that triterpenoids1, 2, and 7maymodulatemacrophages responsiveness to LPS.These three compounds reduced the production of TNF-ğ›¼stimulated with LPS. However, the molecular mechanismsof the induction of TNF-ğ›¼ production in RAW264.7 cells inresponse to LPS remain incompletely understood. Anotherimportant anti-inflammatory activity assay results showedthat compounds 1, 2, and 7 have the potential effect on sup-pression of NF-ğœ…B in a concentration-dependent manner inLPS-stimulated RAW264.7 cells.These similar inhibitions onTNF-ğ›¼ andNF-ğœ…B suggested some close relationship throughEvidence-Based Complementary and Alternative Medicine 7Table 2: Screening anti-inflammation targets over molecule docking of compounds 1â€“5.CompoundnumberMolecules docking resultsTarget name Fit score Norm fit scoreDual specificity mitogen-activated protein kinase kinase 1 (MPKK1) 4.111 0.4567Glucocorticoid receptor (GR) 4.010 0.5012Prothrombin 3.843 0.42711/2 Alpha-1-antitrypsin 3.834 0.6390Glycogen synthase kinase-3 beta 3.786 0.5409ADAM 17 3.726 0.9315Tyrosine-protein kinase SYK 3.712 0.6187Protein kinase C theta type 3.701 0.5287Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) 5.171 0.5745Proto-oncogene tyrosine-protein kinase LCK 4.370 0.43703 Glucocorticoid receptor 4.332 0.5415Glycogen synthase kinase-3 beta 4.298 0.6140Cathepsin B 4.110 0.4566Peroxisome proliferator-activated receptor alpha 4.042 0.5053Prothrombin 3.988 0.6646Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) 3.660 0.40674 Proto-oncogene tyrosine-protein kinase LCK 3.596 0.5137Prothrombin 3.496 0.3885Leukotriene A-4 hydrolase 3.354 0.3727Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) 4.246 0.4718Glucocorticoid receptor 3.931 0.4913Estrogen receptor 3.728 0.5325Leukocyte elastase 3.709 0.41215 Protein kinase C theta type 3.689 0.5270Glycogen synthase kinase-3 beta 3.642 0.5203Proto-oncogene tyrosine-protein kinase LCK 3.626 0.6044Mitogen-activated protein kinase 10 3.596 0.5137Peroxisome proliferator-activated receptor alpha 3.576 0.4470some signal pathway. Previous studies have elucidated somesignal pathways leading to TNF-ğ›¼ in response to LPS. Inparticular, the activation of NF-ğœ…Bmay play a significant rolein LPS-induced expression of TNF-ğ›¼ [26, 27]. We deducedthat compounds 1, 2, and 7 may inhibit LPS-induced TNF-ğ›¼ production through inhibition of NF-ğœ…B signal pathway;similar conclusion has been reported in triterpenoids anti-inflammatory activity studies [28]. It was reported that theactivation of MPKK1 is in the upstream of NF-ğœ…B signalpathway [1]. The computer-aided molecule modeling resultsalso showed compound 1 binding well with MPKK1. Fromthis molecule docking, we further deduced that compounds1 and 2may interact with MPKK1 and consequently suppressthe NF-ğœ…B.Some of the seco-cycloartanes have reported to have anti-HIV-1 activity [29] and anti-HBV (hepatitis B virus) activity[30]. The earliest example was nigranoic acid from stems ofSchisandra sphaerandra that has been demonstrated to becapable of inhibiting HIV viral reverse transcriptase withIC50= 74.1ğœ‡g/mL [31]. Further structure-activation relationexperiment were reported quite recently that cycloartanetriterpenoids with seco structure in ring A shown to inhibitHIV integrase (IN), while cycloartane triterpenoids withoutseco-structure in ring A showed weak or no inhibition at all[32]. The seco-structure seems to be the crucial anti-HIV-1activation related structural feature. Besides, betulinic acidand its derivatives were also extensively reported to have apotent inhibitory activity against human immunodeficiencyvirus type 1 (HIV-1) [33â€“36]. These reports suggest thatcompounds 1â€“5 may also possess certain antiviral activ-ity. Molecule docking provided some well-binding targets,including gag-pol polyprotein, protease, androgen receptor8 Evidence-Based Complementary and Alternative MedicineTable 3: Screening anti-HIV targets over molecule docking of compounds 1â€“5.Compound number Molecules docking resultsTarget name Fit score Norm fit scoreAndrogen receptor 4.294 0.71571/2 Gag-pol polyprotein 4.281 0.3058Glucocorticoid receptor 4.010 0.5012Renin 3.781 0.5401Androgen receptor 4.768 0.79473 Glucocorticoid receptor 4.332 0.5415Renin 4.121 0.5151Gag-pol polyprotein 3.549 0.22184 Androgen receptor 3.359 0.4199Renin 3.347 0.4183Thymidine kinase 3.337 0.4171Androgen receptor 4.022 0.50285 Glucocorticoid receptor 3.931 0.4913Gag-pol polyprotein 3.674 0.2625Protease 3.556 0.4446and renin. Among these, gag-pol polyprotein and proteasehave close relationwithHIV infection.These resultsmay offermore clues for further experiments for anti-HIV-1 potentialand their mechanism.4. ConclusionsWe reported the first seco-triterpenoids isolated from thestem barks of I. difengpi. Two new 3,4;9,10-seco-cycloartanetriterpenoids, as well as three known triterpenoids and twobiosynthetic related squalenes were structurally elucidatedthrough spectral methods, together with comparison withliterature.Our study has demonstrated the anti-inflammatoryactivity of these compounds. They showed remarkable anti-inflammatory activity, especially compounds 1, 2, and 7 anddeserve further considerations towards developing as aneffective anti-inflammatory drug. As reported in the previousliteratures, some seco-cycloartane triterpenoids are capableof inhibiting HIV-1. The computer-aided molecule dockingprovided clues for targets screening and further mechanismresearch. Our study suggested that the triterpenoids from I.difengpi are of great interest as potential leads for naturalproduct-based candidates for further studies.Conflict of InterestsThey have not any possible conflict of interests with thetrademarks included in the paper.AcknowledgmentsThe authors thank Professor Lianna Sun for her helpfulauthentication (Department of Pharmacognosy, School ofPharmacy, Second Medical Military University), ProfessorGenjing Yang for his NMR operating direction (School ofPharmacy, Second Medical Military University), and Fengy-ing Liang (Department of Pharmacy, Changzheng Hospital,Second Medical Military University) and Lina Liao (Depart-ment of Pharmacology, School of Pharmacy, SecondMedicalMilitary University) for their technical assistance on activitystudy. The work was supported by the National NaturalScience Foundation of the Peopleâ€™s Republic of China (Grantno. 81274032), and the Scientific Foundation of Shanghai(Grant no. 11DZ1971301, 08DZ1971600).References[1] A. T. Paul, V. M. Gohil, and K. K. Bhutani, â€œModulating TNF-ğ›¼signaling with natural products,â€ Drug Discovery Today, vol. 11,no. 15-16, pp. 725â€“732, 2006.[2] L. Fang, D. Du, G. Z. Ding et al., â€œNeolignans and glycosidesfrom the stem bark of Illicium difengpi,â€ Journal of NaturalProducts, vol. 73, no. 5, pp. 818â€“824, 2010.[3] I. Kouno, Y. Yanagida, S. Shimono, M. Shintomi, Y. Ito, and Y.Chun-Shu, â€œNeolignans and a phenylpropanoid glucoside fromIllicium difengpi,â€ Phytochemistry, vol. 32, no. 6, pp. 1573â€“1577,1993.[4] I. Kouno, Y. Yanagida, S. Shimono, M. Shintomi, and C. S.Yang, â€œPhenylpropanoids from the Barks of Illicium difengpi,â€Chemical and Pharmaceutical Bulletin, vol. 40, no. 9, pp. 2461â€“2464, 1992.[5] L. Fang, X. J. Wang, S. G. Ma et al., â€œA new sesquiterpenelactone and a new aromatic glycoside from Illicium difengpi,â€Acta Pharmaceutica Sinica B, vol. 1, no. 3, pp. 178â€“183, 2011.[6] P. Huang, M. Nishi, X. Z. Zheng, M. X. Lai, and T. Naknishi,â€œTriterpene acids from the barks of Illicium difengpi,â€ YaoxueXuebao, vol. 32, no. 9, pp. 704â€“707, 1997.[7] R. Yokoyama, J. M. Huang, C. S. Yang, and Y. Fukuyama,â€œNew seco-prezizaane-type sesquiterpenes, jiadifenin with neu-rotrophic activity and 1,2-dehydroneomajucin from Illiciumjiadifengpi,â€ Journal of Natural Products, vol. 65, no. 4, pp. 527â€“531, 2002.Evidence-Based Complementary and Alternative Medicine 9[8] T. J. Schmidt, H. M. Schmidt, E. MuÂ¨ller et al., â€œNew sesquiter-pene lactones from Illicium floridanum,â€ Journal of NaturalProducts, vol. 61, no. 2, pp. 230â€“236, 1998.[9] T. R. R. Pettus, M. Inoue, X. T. Chen, and S. J. Danishefsky,â€œA fully synthetic route the neurotrophic illicinones: synthesesof tricycloillicinone and bicycloillicinone aldehyde,â€ Journal ofthe American Chemical Society, vol. 122, no. 26, pp. 6160â€“6168,2000.[10] Y. N. Liu, X. H. Su, C. H. Huo, X. P. Zhang, Q. W. Shi, and Y. C.Gu, â€œChemical constituents of plants from the genus Illicium,â€Chemistry and Biodiversity, vol. 6, no. 7, pp. 963â€“989, 2009.[11] L. K. Sy and G. D. Brown, â€œA seco-cycloartane from Illiciumverum,â€ Phytochemistry, vol. 48, no. 7, pp. 1169â€“1171, 1998.[12] W. L. Xiao, R. T. Li, S. X. Huang, J. X. Pu, and H. D.Sun, â€œTriterpenoids from the Schisandraceae family,â€ NaturalProduct Reports, vol. 25, no. 5, pp. 871â€“891, 2008.[13] F. He, J. X. Pu, S. X. Huang et al., â€œSchinalactone A, a newcytotoxic triterpenoid from Schisandra sphenanthera,â€ OrganicLetters, vol. 12, no. 6, pp. 1208â€“1211, 2010.[14] X. M. Gao, J. X. Pu, S. X. Huang et al., â€œKadcoccilactones A-J, Triterpenoids from Kadsura coccinea,â€ Journal of NaturalProducts, vol. 71, no. 7, pp. 1182â€“1188, 2008.[15] R. Grougnet, P. Magiatis, S. Mitaku et al., â€œSeco-cycloartanetriterpenes from Gardenia aubryi,â€ Journal of Natural Products,vol. 69, no. 12, pp. 1711â€“1714, 2006.[16] K. Yoshikawa, M. Inoue, Y. Matsumoto et al., â€œLanostanetriterpenoids and triterpene glycosides from the fruit body ofFomitopsis pinicola and their inhibitory activity against COX-1and COX-2,â€ Journal of Natural Products, vol. 68, no. 1, pp. 69â€“73, 2005.[17] T. Nuanyai, R. Sappapan, T. Teerawatananond, N. Muangsin,and K. Pudhom, â€œCytotoxic 3,4-seco-cycloartane triterpenesfromGardenia sootepensis,â€ Journal of Natural Products, vol. 72,no. 6, pp. 1161â€“1164, 2009.[18] K. Pudhom, T. Nuanyai, K. Matsubara et al., â€œAntiangiogenicactivity of 3, 4-seco-cycloartane triterpenes from thai GardeniaSpp. And their semi-synthetic analogs,â€ Bioorganic &MedicinalChemistry Letters, vol. 22, no. 1, pp. 512â€“517, 2012.[19] C. W. Chang, T. S. Wu, Y. S. Hsieh, S. C. Kuo, and P. D.Lee Chao, â€œTerpenoids of Syzygium formosanum,â€ Journal ofNatural Products, vol. 62, no. 2, pp. 327â€“328, 1999.[20] P. Chatterjee, J. M. Pezzuto, and S. A. Kouzi, â€œGlucosidation ofbetulinic acid by Cunninghamella species,â€ Journal of NaturalProducts, vol. 62, no. 5, pp. 761â€“763, 1999.[21] J. H. Yoo, â€œLupane Triterpenoids from Pyrus pyrifolia,â€ NaturalProduct Sciences, vol. 18, no. 1, pp. 13â€“15, 2012.[22] Q. Liu, G. X. Chou, and Z. T. Wang, â€œNew iridoid andsecoiridoid glucosides from the roots of Gentiana manshurica,â€Helvetica Chimica Acta, vol. 95, no. 7, pp. 1094â€“1101, 2012.[23] S. Chowdhury and B. P. Charterjee, â€œArtocarpin-galactomannan interaction: characterization of combiningsite of artocarpin,â€ Phytochemistry, vol. 32, no. 2, pp. 243â€“249,1993.[24] U.Mahmood, V. K. Kaul, and B. Singh, â€œSesquiterpene and longchain ester from Tanacetum longifolium,â€ Phytochemistry, vol.61, no. 8, pp. 913â€“917, 2002.[25] S. Dhuru, D. Bhedi, D. Gophane et al., â€œNovel diarylheptanoidsas inhibitors of TNF-ğ›¼ production,â€ Bioorganic & MedicinalChemistry Letters, vol. 21, no. 12, pp. 3784â€“3787, 2011.[26] S. Khan, O. Shehzad, H. G. Jin et al., â€œAnti-inflammatorymechanism of 15,16-epoxy-3ğ›¼-hydroxylabda-8,13(16),14-trien-7-one via inhibition of LPS-induced multicellular signalingpathways,â€ Journal of Natural Products, vol. 75, no. 1, pp. 67â€“71,2012.[27] W. Cao, X. Q. Li, X. N. Zhang et al., â€œMadecassoside suppressesLPS-induced TNF-ğ›¼ production in cardiomyocytes throughinhibition of ERK, p38, and NF-ğœ…B activity,â€ InternationalImmunopharmacology, vol. 10, no. 7, pp. 723â€“729, 2010.[28] S. S. Nah, I. Y. Choi, B. Yoo, Y. G. Kim, H. B. Moon,and C. K. Lee, â€œAdvanced glycation end products increasesmatrix metalloproteinase-1, -3, and -13, and TNF-ğ›¼ in humanosteoarthritic chondrocytes,â€ The FEBS Letters, vol. 581, no. 9,pp. 1928â€“1932, 2007.[29] S. X. Huang, Q. B. Han, C. Lei et al., â€œIsolation and character-ization of miscellaneous terpenoids of Schisandra chinensis,â€Tetrahedron, vol. 64, no. 19, pp. 4260â€“4267, 2008.[30] Y. C. Shen, Y. C. Lin, M. Y. Chiang, S. F. Yeh, Y. B. Cheng,and C. C. Liao, â€œKadsuphilactones A and B, two new triterpenedilactones from Kadsura philippinensis,â€ Organic Letters, vol. 7,no. 15, pp. 3307â€“3310, 2005.[31] H. D. Sun, S. X. Qiu, L. Z. Lin et al., â€œNigranoic acid, atriterpenoid from Schisandra sphaerandra that inhibits HIV-1reverse transcriptase,â€ Journal of Natural Products, vol. 59, no. 5,pp. 525â€“527, 1996.[32] Z. G. Peng, L. J. Xu, W. C. Ye, P. G. Xiao, and H. S. Chen,â€œEffective components against HIV-1 replicative enzymes iso-lated from plants,â€ Acta Pharmaceutica Sinica, vol. 45, no. 2, pp.235â€“240, 2010.[33] C. Aiken and C. H. Chen, â€œBetulinic acid derivatives as HIV-1antivirals,â€ Trends inMolecularMedicine, vol. 11, no. 1, pp. 31â€“36,2005.[34] S. Chintharlapalli, S. Papineni, S. Liu et al., â€œ2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid,activates peroxisome proliferator-activated receptor ğ›¾ in colonand pancreatic cancer cells,â€ Carcinogenesis, vol. 28, no. 11, pp.2337â€“2346, 2007.[35] T. Kanamoto, Y. Kashiwada, K. Kanbara et al., â€œAnti-humanimmunodeficiency virus activity of YK-FH312 (a betulinicacid derivative), a novel compound blocking viral maturation,â€Antimicrobial Agents andChemotherapy, vol. 45, no. 4, pp. 1225â€“1230, 2001.[36] C. I. Muhanji and R. Hunter, â€œCurrent developments in the syn-thesis and biological activity of HIV-1 double-drug inhibitors,â€CurrentMedicinal Chemistry, vol. 14, no. 11, pp. 1207â€“1220, 2007.Submit your manuscripts athttp://www.hindawi.comStem CellsInternationalHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014MEDIATORSINFLAMMATIONofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Behavioural NeurologyEndocrinologyInternational Journal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Disease MarkersHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014BioMed Research InternationalOncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Oxidative Medicine and Cellular LongevityHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014PPAR ResearchThe Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Journal ofObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014 Computational and  Mathematical Methods in MedicineOphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Research and TreatmentAIDSHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Parkinsonâ€™s DiseaseEvidence-Based Complementary and Alternative MedicineVolume 2014Hindawi Publishing Corporationhttp://www.hindawi.com